Thinking of joining a study?

Register your interest

NCT05133388 | Recruiting | Beta-Thalassemia


The Prevalence of HBB c.93-21 G-A in β Thalassemia Patients
Sponsor:

Assiut University

Information provided by (Responsible Party):

Amira Saber Hamed Ahmed

Brief Summary:

To design an amplification-refractory mutation system (ARMS) for the DNA diagnosis of the IVS I-110 (G>A) [HBB:c.93-21G˃A] mutation. To detect the prevelence of the mutation among Assiut University Hospital patients. Phenotype/genotype correlation of the mutation.

Condition or disease

Beta-Thalassemia

Intervention/treatment

ARMS PCR

Detailed Description:

The β-thalassaemias result from over 300 gene mutations (Kurtoğlu A,et al 2016) These mutations are regionally specific and the spectrum of mutations has been determined for most at-risk populations. The strategy for identifying β-thalassaemia mutations is usually based on knowledge of the common mutations in the ethnic group of the individual being screened (Old JM, 2007). The β globin gene mutation [HBB:c.93-21G˃A] or IVS I-110 (G>A) is the most common β globin gene mutation in the Mediterranean region (Old JM, 2007). . There is no consensus about the % of the mutation among β thalassemic patients in Egypt [has been reported (25.8%) by El-Gawhary et al. 2007, (33.75%) by Soliman et al. 2010, (48%) by El-Shanshory et al. 2014, (22%) by Elmezayen et al. 2015 and (34%) by Elhalfawy et al. 2017]. According to the HbVar site, it represents 33% of the β globin gene mutations in the Egyptians. 28.5% according to Henderson S ,et al 2009 . The mechanism of this mutation depends on formation of a new splicing site resulting in 80% abnormal spliced mRNA and 20% normal mRNA . The molecular characterization of the globin gene mutation is necessary for definite diagnosis, genetic counseling, and in prenatal diagnosis. The amplification-refractory mutation system (ARMS) is a simple method for detecting any mutation involving single base changes or small deletions. The DNA is analyzed after amplification by PCR for Detection of point mutation IVS I-110 (G>A) by Using primer pairs that only amplify individual alleles.}}

Study Type : Observational
Estimated Enrollment : 150 participants
Official Title : The Prevalence of HBB c.93-21 G-A Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals.
Actual Study Start Date : January 30, 2023
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : October 2024

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: All
Criteria
Inclusion Criteria
  • β thalassemia (suspected & clinically diagnosed cases)
Exclusion Criteria
  • Iron deficiency anaemia, anaemia of chronic disease, types of haemolytic anaemias other than thalassemia, other types of thalassemia and Hb variants.

The Prevalence of HBB c.93-21 G-A in β Thalassemia Patients

Location Details


Please Choose a site



The Prevalence of HBB c.93-21 G-A in β Thalassemia Patients

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Recruiting

Egypt,

Faculty of Medicine Assiut University

Assiut, Egypt,

Loading...